Authors
Latest:
Dr. Lavery on the Decline in Esophageal Cancer Diagnoses in Ireland During COVID-19Anita Lavery, MD, MRCP, discusses the decline in esophageal cancer diagnoses in Ireland during the COVID-19 pandemic.
Latest:
Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate CancersRyan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.
Latest:
Dr Hasanov on Actionable Immune-Resistance Targets in RCC With Brain MetastasesElshad Hasanov, MD, PhD, discusses actionable immune-resistance targets in patients with renal cell carcinoma with brain metastases.
Latest:
Dr Kaklamani on the Role of Adjuvant Ribociclib in Early-Stage HR+/HER2– Breast CancerVirginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.
Latest:
Dr Gibson on Addressing Remaining Unmet Needs in GI CancersMichael K. Gibson MD, PhD, discusses the importance of addressing unmet needs related to treatment for patients with gastrointestinal cancers.
Latest:
Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AMLKateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.
Latest:
Dr. Motzer on the Importance of Assessing Health-Related QOL in RCCRobert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.
Latest:
Future Directions in the Management of Acute Myeloid LeukemiaClosing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.
Latest:
Tumor-Infiltrating Lymphocyte Therapy Tackles Treatment Blind Spot in Advanced MelanomaTreatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.
Latest:
Dr. Falkson on the Use of Sacituzumab Govitecan in HR+/HER2- Breast CancerCarla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr Deininger on Long-Term Outcomes With Ponatinib in T315I-Mutant CP-CMLMichael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.
Latest:
Incorporating Treatment Advances Into mRCC ManagementExpectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
Latest:
Frontline Ibrutinib/Venetoclax Elicits Responses in Waldenström Macroglobulinemia, But Has Safety ConcernsThe combination of ibrutinib and venetoclax produced rapid and deep responses in previously untreated patients with Waldenström macroglobulinemia but there was a higher-than-anticipated rate of ventricular arrhythmia that prompted stopping treatment.
Latest:
Hood on the Association Between BRCA Mutations and Primary Tumor Location in PDACRyan Hood, BA, discusses a study investigating the association between BRCA1/2 pathogenic variants and primary tumor location in pancreatic cancer.
Latest:
Grief and Oncology: Lessons From a TraineeAlthough grief never leaves us, we learn how to cope. And as we become seasoned oncologists, I hope we can not only empathize with our patients, but learn to manage this storm of emotions, so that ultimately, we can touch so many more lives in the future.
Latest:
Dr. Liu on the Use of MET-targeted Agents in EGFR-mutant NSCLCStephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.
Latest:
Dr John on the Antitumor Effects of Sulindac in an Obesity-Driven Model of Endometrial CancerCatherine John, MD, discusses the antitumor effects of sulindac on the prevention and treatment of obesity-driven models of endometrial cancer.
Latest:
Advanced Renal Cell Carcinoma: Clinical Practice PearlsDrs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Latest:
Empathy Matters Most: Steven T. Rosen Is a Giant of Cancer Care in Lymphoma“I still have about 250 active patients with blood cancers, and every single one has my cell phone. I do everything in real time....That connection is very important and meaningful for me.”
Latest:
Association Between Clonal Hematopoiesis, RCC, and Cardiovascular DiseaseValisha Shah, MS, discusses the observed association between clonal hematopoiesis and RCC with cardiovascular diseases.
Latest:
Closing Thoughts and Key Takeaways on Small Cell Lung CancerIn a forward-looking discussion, Ticiana Leal, MD; Anne Chiang, MD, PhD; Afshin Dowlati, MD; and Tarita O. Thomas, MD, PhD, offer their concluding insights on the evolving landscape of clinical trials and the future directions of small cell lung cancer (SCLC) treatment, highlighting promising areas of research and potential breakthroughs that may shape the management of this challenging disease in the years to come.
Latest:
Immune Checkpoint Inhibitors Revolutionize Endometrial Cancer TreatmentThe incorporation of immune checkpoint inhibitors has altered the treatment paradigm for endometrial cancer.
Latest:
Overcoming Hurdles to Biosimilar UptakeSanjiv S. Agarwala, MD, explains that biologics have revolutionized the treatment of serious conditions, including cancer, over the past few decades, however, costs are a pressing issue for all providers and biologics are a major culprit.
Latest:
Dr. Federico on Risk Categorization in NeuroblastomaSara M. Federico, MD, discusses risk categorization in neuroblastoma.
Latest:
Dr. Aguirre-Ghiso on Future Research Directions at Albert Einstein Cancer CenterJulio Aguirre-Ghiso, PhD, discusses future research directions being conducted by investigators at the Albert Einstein Cancer Center.
Latest:
Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung CancerRabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.
